{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:59:06Z","timestamp":1788335946968,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40266-021-00851-9","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T03:03:35Z","timestamp":1616641415000},"page":"493-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Sanika","family":"Rege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Carnahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2348-9995.181921","volume":"3","author":"A Avasthi","year":"2016","unstructured":"Avasthi A, Gupta G, Grover S. Pharmacotherapy of dementia. J Geriatr Ment Health. 2016;3:66\u201379.","journal-title":"J Geriatr Ment Health."},{"key":"851_CR2","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2018 Alzheimer\u2019s Disease Facts and Figures. Alzheimers Dement 2018;14(3):367\u2013429. https:\/\/www.alz.org\/media\/HomeOffice\/Facts%20and%20Figures\/facts-and-figures.pdf.","DOI":"10.1016\/j.jalz.2018.02.001"},{"issue":"19","key":"851_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 Census. Neurology. 2013;80(19):1778\u201383.","journal-title":"Neurology."},{"issue":"2","key":"851_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/gps.781","volume":"18","author":"DC Chan","year":"2003","unstructured":"Chan DC, Kasper JD, Black BS, Rabins PV. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry. 2003;18(2):174\u201382.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"12","key":"851_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475\u201383.","journal-title":"JAMA"},{"key":"851_CR6","unstructured":"Benoit M, Arbus C, Blanchard F et al. Professional consensus on the treatment of agitation, aggressive behavior, oppositional behavior and psychotic disturbances in dementia. J Nutr Health Aging. 2006;10(5):410\u20135."},{"issue":"Pt B","key":"851_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","volume":"96","author":"S Lombardo","year":"2015","unstructured":"Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer\u2032s disease pathology and treatment. Neuropharmacology. 2015;96(Pt B):255\u201362.","journal-title":"Neuropharmacology"},{"key":"851_CR8","unstructured":"APA Work Group on Alzheimer\u2019s Disease and other Dementias, Rabins PV, Blacker D et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5\u201356."},{"issue":"5","key":"851_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.amjmed.2006.08.036","volume":"120","author":"MR Farlow","year":"2007","unstructured":"Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer\u2019s disease. Am J Med. 2007;120(5):388\u201397.","journal-title":"Am J Med"},{"issue":"2","key":"851_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jalz.2010.03.016","volume":"7","author":"G Small","year":"2011","unstructured":"Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(2):177\u201384.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"851_CR11","first-page":"145","volume":"105","author":"JM Ellis","year":"2005","unstructured":"Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc. 2005;105(3):145\u201358.","journal-title":"J Am Osteopath Assoc"},{"issue":"4","key":"851_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","volume":"64","author":"GT Grossberg","year":"2003","unstructured":"Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease: getting on and staying on. Curr Ther Res Clin Exp. 2003;64(4):216\u201335.","journal-title":"Curr Ther Res Clin Exp."},{"key":"851_CR13","doi-asserted-by":"crossref","unstructured":"Scharre DW, Vekeman F, Lefebvre P Mody-Patel N,\u00a0Kahler KH,\u00a0Duh MS. Use of antipsychotic drugs in patients with Alzheimer\u2019s disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. Drugs Aging. 2010;27(11):903\u201313.","DOI":"10.2165\/11584290-000000000-00000"},{"key":"851_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000047952","volume":"47","author":"CG Ballard","year":"2002","unstructured":"Ballard CG. Advances in the treatment of Alzheimer\u2019s disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47:64\u201370.","journal-title":"Eur Neurol"},{"issue":"4","key":"851_CR15","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1073\/pnas.98.4.2089","volume":"98","author":"DS Woodruff-Pak","year":"2001","unstructured":"Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA. 2001;98(4):2089\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"851_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2174\/138920207783769549","volume":"8","author":"A Lle\u00f3","year":"2007","unstructured":"Lle\u00f3 A. Current therapeutic options for Alzheimer\u2019s disease. Curr Genom. 2007;8(8):550\u20138.","journal-title":"Curr Genom"},{"key":"851_CR17","doi-asserted-by":"crossref","unstructured":"Farlow M, Potkin S, Koumaras B, Veach J, Mirski D et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo. 26-week. Alzheimer disease trial. Arch Neurol. 2003;60(6):843\u20138.","DOI":"10.1001\/archneur.60.6.843"},{"issue":"4","key":"851_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1017\/S104161020200858X","volume":"14","author":"S Gauthier","year":"2002","unstructured":"Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer\u2019s disease. Int Psychogeriatr. 2002;14(4):389\u2013404.","journal-title":"Int Psychogeriatr"},{"key":"851_CR19","doi-asserted-by":"crossref","unstructured":"Cummings JL, McRae T, Zhang R, Donepezil-Sertraline Study Group et al. Effects of donepezil on neuropsychiatrie symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14 (7):605\u201312.","DOI":"10.1097\/01.JGP.0000221293.91312.d3"},{"issue":"Suppl. 3","key":"851_CR20","first-page":"A468","volume":"54","author":"JL Cummings","year":"2000","unstructured":"Cummings JL, Anand R, Koumaras B, et al. Rivastigmine provides behavioral benefits to Alzheimer\u2019s disease patients residing in a nursing home: findings from a 26-week trial [abstract]. Neurology. 2000;54(Suppl. 3):A468\u20139.","journal-title":"Neurology."},{"issue":"3","key":"851_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","volume":"161","author":"JL Cummings","year":"2004","unstructured":"Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer\u2019s disease. Am J Psychiatry. 2004;161(3):532\u20138.","journal-title":"Am J Psychiatry"},{"issue":"Suppl1","key":"851_CR22","first-page":"S87","volume":"51","author":"C Andrade","year":"2009","unstructured":"Andrade C, Radhakrishnan R. Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia. Indian J Psychiatry. 2009;51(Suppl1):S87\u201392.","journal-title":"Indian J Psychiatry."},{"issue":"9","key":"851_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","volume":"169","author":"M Steinberg","year":"2012","unstructured":"Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900\u20136.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"851_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1533317510390351","volume":"26","author":"V Mittal","year":"2011","unstructured":"Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(1):10\u201328.","journal-title":"Am J Alzheimers Dis Other Demen."},{"issue":"10","key":"851_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/gps.2232","volume":"24","author":"Z Feng","year":"2009","unstructured":"Feng Z, Hirdes JP, Smith TF, et al. Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriatr Psychiatry. 2009;24(10):1110\u20138.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"8","key":"851_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1017\/S1041610211000755","volume":"23","author":"RB Wetzels","year":"2011","unstructured":"Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int Psychogeriatr. 2011;23(8):1249\u201359.","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"851_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2165\/00002512-200421060-00004","volume":"21","author":"DC Suh","year":"2004","unstructured":"Suh DC, Arcona S, Thomas SK, et al. Risk of antipsychotic drug use in patients with Alzheimer\u2019s disease treated with rivastigmine. Drugs Aging. 2004;21(6):395\u2013403.","journal-title":"Drugs Aging"},{"issue":"1","key":"851_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jamda.2005.04.007","volume":"7","author":"S Narayanan","year":"2006","unstructured":"Narayanan S, Beusterien KM, Thomas SK, Musher J, Strunk B. Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc. 2006;7(1):12\u20136.","journal-title":"J Am Med Dir Assoc."},{"issue":"3","key":"851_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1017\/S1041610214001975","volume":"27","author":"Y Okumura","year":"2015","unstructured":"Okumura Y, Togo T, Fujita J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. Int Psychogeriatr. 2015;27(3):407\u201315.","journal-title":"Int Psychogeriatr"},{"issue":"8","key":"851_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/pds.1739","volume":"18","author":"M Robinson","year":"2009","unstructured":"Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(8):659\u201364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"851_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/070674371305800404","volume":"58","author":"J Lachaine","year":"2013","unstructured":"Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the R\u00e9gie de l\u2019Assurance Maladie du Qu\u00e9bec database. Can J Psychiatry. 2013;58(4):195\u2013200.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"851_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4140\/TCP.n.2018.273.","volume":"33","author":"AT Blaszczyk","year":"2018","unstructured":"Blaszczyk AT, Mang BH, Garza H, Mathys M. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing. Consult Pharm. 2018;33(5):273\u201382.","journal-title":"Consult Pharm."},{"key":"851_CR33","unstructured":"Centers for Medicare & Medicaid Services. Medicare Standard Analytical Files: Identifiable Data Files. [online] http:\/\/www.cms.hhs.gov\/IdentifiableDataFiles\/02_StandardAnalyticalFiles.asp. Accessed Nov 2018."},{"key":"851_CR34","unstructured":"Centers for Medicare & Medicaid Services. CMS Statistics Reference Booklet https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/CMSStatistics-Reference-Booklet\/index.html. Accessed Nov 2018."},{"key":"851_CR35","unstructured":"Research Data Assistance Center (ResDAC): Available CMS Data http:\/\/www.resdac.org\/cms-data\/file-availability. Accessed Nov 2018."},{"key":"851_CR36","unstructured":"Research Data Assistance Center (ResDAC): Record Layouts. http:\/\/www.resdac.org\/resconnect\/record-layouts. Accessed Nov 2018."},{"key":"851_CR37","unstructured":"CMS Chronic Conditions Data Warehouse (CCW) Data Dictionaries https:\/\/ccwdata.org\/web\/guest\/data-dictionaries. Accessed Nov 2018."},{"key":"851_CR38","unstructured":"CMS Chronic Conditions Data Warehouse (CCW) Data Dictionaries. https:\/\/ccw-chronic-condition-algorithms.pdf. Accessed Nov 2018."},{"key":"851_CR39","unstructured":"AHFS Drug Information\u00ae\u20142019, American Society of Health-System Pharmacists. http:\/\/online.statref.com\/document\/cQfe8yqMRNqgSGqm4Qo8Qj. Accessed Nov 2018."},{"key":"851_CR40","unstructured":"Andersen RM. A Behavioral model of families\u2019 use of health services. (Research Series 25). Center for Health Administration Studies. 1968: Chicago: University of Chicago."},{"key":"851_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"RM Andersen","year":"1995","unstructured":"Andersen RM. Revisiting the Behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36:1\u201310.","journal-title":"J Health Soc Behav"},{"key":"851_CR42","unstructured":"HCUP CCS. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp."},{"issue":"Suppl 3","key":"851_CR43","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1097\/MLR.0000000000000026","volume":"52","author":"E Chrischilles","year":"2014","unstructured":"Chrischilles E, Schneider K, Wilwert J, et al. Beyond comorbidity: expanding the definition and measurement of complexity among older adults using administrative claims data. Med Care. 2014;52(Suppl 3):S75\u201384.","journal-title":"Med Care"},{"key":"851_CR44","doi-asserted-by":"crossref","unstructured":"Birks J. Cholinesterase Inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.","DOI":"10.1002\/14651858.CD005593"},{"key":"851_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"P Raina","year":"2008","unstructured":"Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379\u201397.","journal-title":"Ann Intern Med"},{"issue":"1","key":"851_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/fhep-2012-0037","volume":"16","author":"LH Nicholas","year":"2013","unstructured":"Nicholas LH. Better quality of care or healthier patients? Hospital utilization by medicare advantage and fee-for-service enrollees. Forum Health Econ Policy. 2013;16(1):137\u201361.","journal-title":"Forum Health Econ Policy."},{"issue":"10","key":"851_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","volume":"20","author":"G Wilcock","year":"2003","unstructured":"Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of alzheimer\u2019s disease. Drugs Aging. 2003;20(10):777\u201389.","journal-title":"Drugs Aging"},{"issue":"2","key":"851_CR48","first-page":"211","volume":"3","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211\u201325.","journal-title":"Clin Interv Aging"},{"issue":"9","key":"851_CR49","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/jgs.15442","volume":"66","author":"PA Rochon","year":"2018","unstructured":"Rochon PA, Gruneir A, Gill SS, et al. Initial cholinesterase inhibitor therapy dose and serious events in older women and men. J Am Geriatr Soc. 2018;66(9):1692\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"851_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jalz.2009.09.001","volume":"6","author":"PJ Lin","year":"2010","unstructured":"Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer\u2019s disease case definitions using Medicare claims and survey data. Alzheimers Dement. 2010;6(4):334\u201341.","journal-title":"Alzheimers Dement."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00851-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T04:39:18Z","timestamp":1623991158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00851-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00851-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"28 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Aparasu has received research funding from Astellas Inc., Incyte Corp., and Novartis Inc. for projects unrelated to the current work. Sanika Rege, Ryan M. Carnahan, Michael L. Johnson, Hua Chen, and Holly M. Holmes have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the University of Houston Committee for the Protection of Human Subjects under the exempt category.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data on which this study is based are not available due to the CMS data use restrictions for research identifiable files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concept and design: All authors. Acquisition of data: Aparasu and Rege. Data analysis: Rege. Data interpretation: All authors. Manuscript drafting: Rege and Aparasu. Manuscript critical revision and approval: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}